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Salt and cardiovascular disease
Legislation to cut levels of salt in processed food is necessary and justified
Blood pressure is the most powerful predictor of stroke 
and other cardiovascular events. The importance of salt 
(sodium chloride) intake in determining blood pressure 
and the incidence of hypertension is well established. 
Furthermore, randomised controlled clinical trials of 
moderate reductions in salt intake show a dose depend-
ent cause-effect relation and lack of a threshold effect 
within usual levels of salt intake in populations world-
wide.1 The effect is independent of age, sex, ethnic ori-
gin, baseline blood pressure, and body mass.
Prospective studies,2-5 with one exception,6 also 
indicate that higher salt intake predicts the incidence 
of cardiovascular events. While widespread support 
exists for reducing salt intake to prevent cardiovascular 
disease, the lack of large and long randomised trials on 
the effects of salt reduction on clinical outcomes has 
encouraged some people to argue against a policy of 
salt reduction in populations.6
In this week’s BMJ, Cook and colleagues7 report the 
long term effects of reduced dietary sodium on cardio-
vascular disease in people participating in the controlled 
randomised trials of hypertension prevention follow-up 
studies (TOHP I and II). More than 3000 participants 
without hypertension were randomised to a reduced 
sodium intake for 18 months (TOHP I) or 36-48 months 
(TOHP II), or to a control arm. The reductions in 
sodium intake were 44 mmol/day and 33 mmol/day 
(equivalent to ~2.6 g and ~2.0 g of salt), respectively. 
The results show that people originally allocated to 
either sodium reduction group had a 30% lower inci-
dence of cardiovascular events in the next 10-15 years, 
irrespective of sex, ethnic origin, age, body mass, and 
blood pressure. The benefits exceed those estimated by 
a recent meta-analysis.8 Cook and colleagues’ study is 
the first to report a beneficial effect of dietary salt reduc-
tion on cardiovascular outcomes based on randomised 
trial data. 
The study strengthens the support for dietary recom-
mendations for lower salt intake to prevent cardiovascu-
lar disease in the general population. In 1985, the World 
Health Organization recommended that the average salt 
intake should be reduced to 5 g per day or less. How-
ever, few countries have policies for targeted reduction 
in salt intake.
Differences exist between developed and developing 
countries. In Westernised countries, people derive salt 
mostly from bread and processed food and only a small 
proportion comes from discretionary use (up to 20%). A 
population wide policy of salt reduction in developed 
countries can only be implemented with the collabora-
tion of the food industry. Over the years, however, the 
need to sustain a profitable market has led to opposition 
from the food industry or slow progress.9
In England and Wales some progress has been made, 
but levels of salt intake are still far from the government’s 
recommended 6 g of salt per day. Future options are to 
do nothing, to establish voluntary target levels of salt 
for a wide range of foods, or to legislate so that the food 
industry has to comply. Given the inertia of the past 20 
years, the first option would not contribute to progress. 
The “voluntary” option would support existing work, 
but it is unlikely to achieve the set targets. The recent 
position of the industry in rejecting the “traffic light” 
proposal for labelling, whereby highly salted foods 
would carry a red alert warning, is one measure of the 
gap still remaining. The legislation option would require 
the food industry to reduce the salt content of processed 
food to within set levels. The experience in Finland sug-
gests that legislation has added value to the previous 
option and at this stage is necessary and justified.
Conversely, in many developing countries, like those 
of sub-Saharan Africa, where the main source of salt is 
still discretionary, community based and context spe-
cific initiatives can be effective and should be pursued,10 
given the increasing burden of cardiovascular disease 
related to hypertension.
Without considerably modifying the environment by 
allowing greater availability of low salt foods, people in 
developed countries will find it difficult to exercise their 
“choice” when trying to reduce dietary salt. Doctors and 
health professionals have long used dietary counselling 
to deliver non-pharmacological management of hyper-
tension. Advising patients to reduce salt intake with a 
lifestyle package quickly delivered in a busy primary 
care setting is ineffective, however.11 A baseline assess-
ment of salt intake (through a 24 h urinary collection 
for the measurement of sodium) is not part of the UK’s 
National Service Framework requirements and is not 
included in the Quality and Outcome Framework. The 
current system is therefore unlikely to make health pro-
fessionals and consumers more aware of how much salt 
people eat or to increase motivation and knowledge 
on how to reduce it. In a climate of scarce healthcare 
resources, one of the most cost effective ways to reduce 
the burden of cardiovascular disease is being over-
looked.12 And yet the evidence gets stronger.
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In March 2007, the North American Menopause Society 
(NAMS) published an updated position statement 
on the use of hormone therapy in postmenopausal 
women.1 NAMS recommends hormone therapy, 
which is a highly effective treatment for hot flushes and 
vaginal atrophy,2 as first line treatment for women with 
moderate to severe symptoms. It is also effective for 
preventing osteoporotic fractures,3 4 but NAMS recom-
mends that hormone therapy for this purpose should be 
weighed against potential harm and that other approved 
preventive treatments such as bisphosphonates should 
be considered. These recommendations are clear, 
simple, and based on solid evidence from many ran-
domised controlled trials.
However, NAMS recommendations are less clear 
in several other areas. For example, after clearly stat-
ing that hormone therapy increases risk of venous 
thromboembolic events and stroke, no advice is pro-
vided about how clinicians and patients should use this 
information. Similarly, NAMS notes that risk of breast 
cancer is increased in women who use oestrogen plus 
progestin for five years or more, but no recommendation 
is given about its use in women at high risk of breast 
cancer. The statement also notes that treatment with hor-
mone therapy in women over 65 years increases risk for 
dementia,5 6 and that no evidence is available regarding 
effects on dementia from clinical trials in younger 
women, but there is no clear statement that hormone 
therapy should not be used to prevent dementia.
NAMS published a position statement on use of 
postmenopausal hormone therapy in 2004, and since 
then no large randomised trials have been published 
that would require revision of guidelines. What then 
has changed since the earlier statement? The main 
changes in the new position statement reflect the belief 
of NAMS panelists that, if used during or shortly after 
the menopause, hormone therapy may not increase 
risk of coronary heart disease. Evidence to support 
this “timing hypothesis” comes from studies of cas-
trated animals and post hoc analyses of observational 
studies, but primarily rests on subgroup analyses of 
data from the two women’s health initiative randomised 
trials.7 Analyses that pooled data from the women’s 
health initiative trial of oestrogen alone and of 
oestrogen plus progestin show no clear difference in 
risk for coronary heart disease associated with use of 
hormone therapy in women in their 50s compared with 
older women. However, women treated with hormone 
therapy within 10 years of the menopause seemed to 
have a reduced risk of heart disease (hazard ratio 0.76, 
95% confidence interval 0.50 to 1.16), whereas those who 
had undergone the menopause more than 20 years ago 
had an increased risk (1.28, 1.03 to 1.58; P value for 
interaction 0.02). These data are not entirely convincing, 
as about 137 comparisons were performed, and several 
statistically significant findings would be expected to 
occur by chance. The “timing hypothesis” will probably 
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Postmenopausal hormone therapy
Symptoms should be treated with lowest effective dose of hormone therapy 
for the shortest time possible
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Pneumonia occurring during mechanical ventilation 
(ventilator associated pneumonia) is the most com-
mon infection acquired by patients in intensive care. 
Reported rates range from 9% to 67% and 4.4 to 15.7 
cases per 1000 ventilator days.1 In this week’s BMJ, a 
systematic review by Chan and colleagues2 assesses 
the effect of oral decontamination with antiseptics 
on ventilator associated pneumonia and mortality in 
mechanically ventilated adults.
Ventilator associated pneumonia prolongs lengths 
of stay in intensive care and hospital, and it increases 
costs of care and possibly increases mortality.3 4 The 
prevention of this infection is therefore a high priority 
for infection control in intensive care.5
Preventive procedures deal with three broad areas: 
prevention of cross transmission; upper digestive 
tract colonisation and the risk of inhalation; and 
maintenance and care of the artificial and natural 
airways.5-7 Because the oropharynx and upper 
intestinal tract are the major sources of organisms 
causing pneumonia in intensive care, they would 
appear to be good targets for preventive measures.
Many studies have assessed prevention using anti-
microbials administered via various routes, alone or 
combined. “Selective digestive tract decontamination,” 
which uses various combinations of systemic and topi-
cal (oropharyngeal and intestinal) antibiotics has gen-
erated the largest number of trials, summarised in at 
least eight successive systematic reviews, including one 
by the Cochrane group.8 In the latest update, which 
included 36 trials involving 6922 patients, topical and       
combined systemic antibiotics reduced respiratory 
tract infections (odds ratio 0.35, 95% confidence inter-
val 0.29 to 0.41). Mortality was also reduced with the 
combination (0.78, 0.68 to 0.89), but not with topical 
(intestinal, with or without oropharyngeal) antibiotics 
alone, despite a comparable effect on rates of pneu-
monia.8 Selective digestive tract decontamination has     
not been accepted widely5 7 because of controversy 
about the balance of benefits and risks—particularly 
on overall use of antibiotics and selection of resistant 
microorganisms with prolonged use—and uncertainty 
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never be directly confirmed or refuted, because the 
low absolute rate of coronary heart disease among peri-
menopausal women would require many thousands of 
perimenopausal and early postmenopausal women to be 
randomised to treatment or placebo for more than a dec-
ade. Even if the timing hypothesis is true, little evidence 
exists that other risks of hormone therapy vary with time 
since menopause.7 Finally, the timing hypothesis has 
little impact on clinical care. Even if we reject the timing 
hypothesis and assume that the overall risks documented 
in the women’s health initiative trials apply to younger 
women, the absolute risk associated with taking hormone 
therapy for a few years to treat menopausal symptoms is 
low, and worth the benefit of symptom relief.
The NAMS position statement is not an evidence 
based guideline as defined by the UK National Insti-
tute for Health and Clinical Excellence8 or the US Pre-
ventive Services Task Force.9 A search of Medline (but 
not other databases) was performed, but data were not 
systematically abstracted or synthesised. References 
are provided in a bibliography, but it is not possible to 
determine which studies were used to support specific 
recommendations. NAMS uses a consensus process, in 
which selected experts are given recent references and 
asked to provide their opinions. The position statement 
is based on agreement among at least two thirds of the 
panel—more a majority than a consensus. NAMS is to 
be congratulated for providing financial disclosures of 
panel members, but it is concerning that these are so 
extensive.
Another worrying aspect of the 2007 NAMS position 
statement is that it suggests that use of postmenopausal 
hormone therapy is complicated. While some details 
are unclear or complex, the basic approach to using 
postmenopausal hormone therapy is clear and simple: 
treat bothersome menopausal symptoms with the lowest 
effective dose of hormone therapy for the shortest time 
possible and do not use it to prevent disease.
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Preventing ventilator associated pneumonia  
oral antiseptic agents should be part of a multi faceted preventive care package
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about the respective or added value of components 
of the antimicrobial regimens tested, whether topical, 
systemic, or both.
Limiting the application of topical antibiotics to the 
oropharynx is one option, but too few studies have 
investigated this question.2 8 In addition, infection rates 
may be difficult to interpret because of the spill over 
of antibiotics from the oropharynx into the lower air-
ways. Of even more concern is the presumably high 
risk of selection of resistant strains in an environment 
both heavily loaded with microorganisms and exposed 
to rapid colonisation by hospital acquired organisms. 
Applying antiseptics rather than antibiotics to the 
oropharynx might be a solution, but until recently few 
data were available on this intervention.5 9 
The review by Chan and colleagues of seven trials  
involving 2144 patients found that topical antiseptics     
significantly reduced the rate of pneumonia (relative 
risk 0.56, 0.39 to 0.81; P=0.002).2 The findings are 
comparable to those of another recently published 
review (limited to topical chlorhexidine), which also 
included seven trials but only 1650 patients.9 The two 
reviews differ by the selection or exclusion of two trials 
each. Specifically, Chan and colleagues2 were able to 
include the most recently published placebo controlled 
trial conducted in 954 patients who had undergone car-
diovascular surgery, which showed a significant reduc-
tion in the rate of pneumonia (9.3% v 15.8%; P=0.002) 
with 0.12% chlorhexidine applied four times daily to 
the nasal mucosa and oropharynx compared with a 
placebo similarly applied.10 However, as is the case 
for topical antibiotics only,8 the review by Chan and 
colleagues found that oropharyngeal antiseptics had 
no impact on mortality (0.96, 0.69 to 1.33; P=0.82) or 
length of stay in the intensive care unit.2 
Results varied greatly across the trials included in 
the review (P=0.07),2 which might in part be explained 
by differences in design, populations studied (medical 
versus surgical or mixed), duration of mechanical ven-
tilation, and type and frequency of antiseptics applied. 
For example, 60% of patients included in the review2 
had received cardiac surgery and had a short (mean 
<48 h) exposure to mechanical ventilation and treat-
ment.10 However, in subgroup analyses, the effect size 
was comparable with short (<48 h) or longer duration 
of mechanical ventilation, although it was significant 
only in the larger group of surgical patients.2 Further 
studies should deal with these problems and confirm 
the efficacy of antiseptics, especially in larger groups 
of medical patients in intensive care who receive pro-
longed mechanical ventilation.
Preventing ventilation associated pneumonia is dif-
ficult, because of the insertion of an indwelling device 
within a contaminated area. Only substituting invasive 
mechanical ventilation with non-invasive ventilation, 
when appropriate, can circumvent this problem.11 
However, implementing a group of multifaceted and 
targeted preventive measures—including education 
of personnel, semirecumbent positioning of patients, 
care of ventilator circuit, and no-touch suctioning—can 
substantially reduce rates of infection.12 The data now 
available, while still limited, suggest that oropharyngeal 
care with antiseptics may be included in such preven-
tive strategies. However, as is the case for antibiot-      
ics, the risk of a long term effect of widespread use of 
antiseptics on the emergence and spread of bacterial 
resistance to these agents needs to be considered.
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